RxDoctor Payments Data

Carter Edwards, MD

Internal Medicine · Greenville, SCNPI 1073952131

Payments from drug & device makers

$1,704in general payments, 2019–2025

Across 99 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$484
  • Novo Nordisk$480
  • Exact Sciences$135
  • Esperion Therapeutics, Inc.$70
  • Inspire Medical Systems, Inc.$67
  • Amgen$58
  • plus $410 from 14 others

What the payments were for

  • Food & beverage$1,704100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,704 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$287,628
Medicare patients
441
Services billed
4,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide180$312,483
EliquisApixaban195$188,984
JardianceEmpagliflozin85$109,541
MounjaroTirzepatide88$94,048
XareltoRivaroxaban59$49,274
CreonLipase/Protease/Amylase18$35,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$35,002
JanuviaSitagliptin Phosphate41$30,326
RybelsusSemaglutide21$28,001
LinzessLinaclotide18$26,403
Tresiba Flextouch U-100Insulin Degludec29$24,925
EntrestoSacubitril/Valsartan20$22,709
Aimovig AutoinjectorErenumab-Aooe17$22,446
TrulicityDulaglutide11$19,756
Spiriva RespimatTiotropium Bromide15$18,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$480$340,484201 claims
PfizerEliquis$36$188,984195 claims
Boehringer IngelheimJardiance, Spiriva Respimat$12$128,465100 claims
Lilly USA, LLCMounjaro, Trulicity$484$113,80399 claims
AbbVieCreon, Linzess, Ubrelvy, Synthroid$25$84,939102 claims
GSKTrelegy Ellipta, Anoro Ellipta$30$52,79954 claims
MerckJanuvia$49$30,32641 claims
NovartisEntresto$13$22,70920 claims
Astellas Pharma US IncMyrbetriq$56$11,63812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →